Markets Jittery as Powell Probe, Tariff Ruling, and Iran Tensions Collide

Markets Jittery as Powell Probe, Tariff Ruling, and Iran Tensions Collide

Escalating tariffs, Iran-related tensions, and defense spending are emerging as key drivers of volatility and higher yields.

Big Pharma Gains Spotlight Ahead of JPM Conference

Pharmaceutical executives are entering 2026 with renewed confidence as pricing and tariff pressures from Washington fade, lifting investor sentiment ahead of the J.P. Morgan Healthcare Conference.

Trump’s Ukraine Plan Hits New Hurdles After Call With Putin

President Donald Trump’s effort to broker an end to the war in Ukraine hit new uncertainty after Russian President Vladimir Putin said he would revisit Moscow’s negotiating stance following an alleged Ukrainian drone attack—claims Kyiv has dismissed as false.

According to the Trump administration, lowering prices on 15 Medicare drugs will save taxpayers billions

The administration announced that pharmaceutical companies agreed to reduce Medicare prices on 15 high-cost drugs—changes that could save taxpayers billions when they take effect in 2027.

Questions Raised Over Trump’s Tariff Authority

Henrietta Treyz, Co-Founder at Veda Partners, weighs in on the implications of the Supreme Court’s upcoming ruling on presidential tariff authority, as the EU raises concerns over the expanding list of its products facing steep U.S. metal tariffs.